Product News

Share this article:

FDA approved labeling changes on Vyvance, Shire's ADHD drug, extending the product's efficacy to 13 hours in children 6 to 12. According to a Shire release, the label changes represent the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients including in the labeling. Consumer and professional campaign materials in support of the label changes are currently in the works, according to a spokesperson.


Bayer Diabetes Care launched a new A1C monitor – A1CNow Selfcheck – enabling people with diabetes to check their A1C level at home. The product is now available without a prescription, and provides at-home results within five minutes, according to a statement.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.